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Abstract 
Background: Accurate biomarkers to diagnose infection are lacking. Studies reported good performance of pancre‑
atic stone protein (PSP) to detect infection. The objective of the study was to determine the performance of PSP in 
diagnosing infection across hospitalized patients and calculate a threshold value for that purpose.
Methods: A systematic search across Cochrane Central Register of Controlled Trials and MEDLINE databases (1966–
March 2019) for studies on PSP published in English using ‘pancreatic stone protein’, ‘PSP’, ‘regenerative protein’, ‘lithos‑
tatin’ combined with ‘infection’ and ‘sepsis’ found 44 records. The search was restricted to the five trials that evaluated 
PSP for the initial detection of infection in hospitalized adults. Individual patient data were obtained from the investi‑
gators of all eligible trials. Data quality and validity was assessed according to PRISMA guidelines. We choose a fixed‑
effect model to calculate the PSP cut‑off value that best discriminates infected from non‑infected patients.
Results: Infection was confirmed in 371 of 631 patients. The median (IQR) PSP value of infected versus uninfected 
patients was 81.5 (30.0–237.5) versus 19.2 (12.6–33.57) ng/ml, compared to 150 (82.70–229.55) versus 58.25 (15.85–
120) mg/l for C‑reactive protein (CRP) and 0.9 (0.29–4.4) versus 0.15 (0.08–0.5) ng/ml for procalcitonin (PCT). Using a 
PSP cut‑off of 44.18 ng/ml, the ROC AUC to detect infection was 0.81 (0.78–0.85) with a sensitivity of 0.66 (0.61–0.71), 
specificity of 0.83 (0.78–0.88), PPV of 0.85 (0.81–0.89) and NPV of 0.63 (0.58–0.68). When a model combining PSP and 
CRP was used, the ROC AUC improved to 0.90 (0.87–0.92) with higher sensitivity 0.81 (0.77–0.85) and specificity 0.84 
(0.79–0.90) for discriminating infection from non‑infection. Adding PCT did not improve the performance further.
Conclusions: PSP is a promising biomarker to diagnose infections in hospitalized patients. Using a cut‑off value of 
44.18 ng/ml, PSP performs better than CRP or PCT across the considered studies. The combination of PSP with CRP 
further enhances its accuracy.
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Background
Severe infections are leading causes of morbidity and 
mortality among hospitalized patients [1, 2]. Early 
detection of life-threatening infection is crucial to 
improving outcomes [1]. To date, none of the circu-
lating blood biomarkers or signatures of the immune 
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response that have been investigated [3, 4] detect 
life-threatening infection quickly enough and with an 
acceptable certainty [5]. Two markers [C-reactive pro-
tein (CRP) and procalcitonin (PCT)] are widely used 
[6–10] despite their sub-optimal performance [11].
Pancreatic stone protein (PSP) is a pro-inflammatory 
mediator that binds to polymorphonuclear cells and 
triggers their activation in  vitro (reviewed in [12]); it 
is a recently described biomarker of infection whose 
performance has been thoroughly evaluated in several 
patient populations and in different clinical settings, 
including emergency rooms (ERs) [13] and intensive 
care units (ICUs) [14–18]. PSP was able not only to 
diagnose infection [14, 15, 18] but also to character-
ize its severity [16, 17] as well as to predict its out-
come [16, 17, 19]. Nevertheless, a clinically useful PSP 
threshold level has not yet been defined.
We aimed to perform an individual patient level 
meta-analysis of published data to determine the per-
formance of PSP in detecting infection, to propose a 
threshold value for that purpose and to validate it 
across heterogeneous populations.
Methods
Search strategy and selection criteria
A systematic literature search was performed based 
on the following search strategy prepared according to 
PRISMA individual patient data guidelines (Additional 
file 1: Tables S1 and S2) [20]. The databases searched 
were the Cochrane Central Register of Controlled Tri-
als (CENTRAL) and MEDLINE (1966–March 2019). 
The search was restricted to original human clinical 
trials on PSP/reg published in English before March 
2019 that assessed the performance of PSP for the ini-
tial detection of infection in hospitalized adults (see 
definition of infection for each study in Additional 
file  1: Table  S3). We used ‘pancreatic stone protein’, 
‘PSP’, ‘regenerative protein’, ‘infection’, ‘sepsis’ and 
‘lithostatin’ as keywords. Paediatric trials and autopsy 
studies were excluded.
Two reviewers (JP and YAQ) independently assessed 
trial eligibility based on titles, abstracts, full-text 
reports and further information from investigators as 
needed (Fig.  1). Study protocols and unedited data-
bases containing anonymized individual patient data 
were obtained from investigators of all eligible trials.
The Cantonal Ethical Committee of the State of Bern 
(#2018-01356) reviewed and approved the protocol of 
this systematic review and meta-analysis in 2018 (see 
Additional file 2: Appendix) and the respective ethical 
committees approved all specific studies.
Assessment of data validity
All raw data were received with patient-specific 
anonymized identification and included at least the fol-
lowing information: age, sex, confirmed infection/non-
infection and values of PSP, CRP and PCT. For Klein 
et  al., we did not receive PCT values or gender data. 
Death outcomes and days to death were described only 
in Keel et al. and Llewelyn et al. Data from each trial were 
first checked for duplicates and then against reported 
results. Queries were resolved with the principal inves-
tigator, trial data manager or statistician when needed. 
Cases with missing PSP values were excluded. In all eli-
gible subjects, PSP levels were measured according to 
the same protocols and techniques developed by Rolf 
Graf ’s team at the Universitätsspital Zürich, Switzerland. 
Llewelyn et  al. used plasma instead of serum; however, 
we did not observe any considerable variations in main 
PSP values between plasma and serum. Biomarker data 
were checked for consistency and variability within and 
between studies to detect possible bias using known 
ranges, boxplots and estimated densities of log-trans-
formed values (Additional file 3: Figures S1 and S2). PCT 
exhibits increased within- and between-study variabil-
ity (higher interquartile range and much higher outlier 
points) while compared to PSP and CRP.
Data analysis
We included all adult patients admitted to either an ER 
or an ICU and in whom PSP was measured to diagnose 
infection. For both studies with multiple time points, we 
restricted the analysis on day 5 after severe trauma for 
Keel et  al. and on day 2 after cardiac surgery for Klein 
et  al. The primary objective was to calculate the opti-
mal PSP threshold value to discriminate infected from 
non-infected patients. The secondary objectives were: 
(1) to compare the PSP accuracy, its negative and posi-
tive predicting values as well as its positive and negative 
likelihood ratio to those of PCT and CRP for detecting 
infected patients, and finally (2) to explore the value of 
models using different combinations of the three bio-
markers to further improve the detection of infection.
Because data exploration showed skewness (Additional 
file  3: Figures  S1 and S2) in most continuous variables, 
these were reported as medians and interquartile ranges 
(IQRs). Categorical variables were reported as frequen-
cies and percentages.
Statistical analysis
Meta‑analysis model selection and heterogeneity assessment
We performed an individual patient data meta-analysis 
and evaluated three models according to the approach 
proposed by Steyerberg et  al. [21] (Additional file  1: 
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Table  S4 and Additional file  4: Supplemental Meth-
ods). A ‘fully stratified’ random-effect model (random 
intercept and random PSP effect) was compared to a 
mixed-effects model with random study effect but fixed 
treatment effect, and a fixed-effect model (Additional 
file 1: Tables S4 and S5). Even though the fully stratified 
and the mixed-effects model provided better ROC AUCs 
(Additional file  1: Tables S7 and S9), we selected the 
fixed-effect model as it was the only one among the three 
models considered that provided a unique PSP threshold 
(Additional file 1: Tables S6, S7 and S9).
Single biomarker approach
ROC curves were constructed for all untransformed bio-
markers of interest (PSP, PCT and CRP) by varying the 
cut-off values distinguishing infection from non-infec-
tion. The best PSP, PCT and CRP cut-off values to detect 
infected patients were determined using the Youden’s 
Fig. 1 Study selection
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index applied to their respective ROC curves. The cut-off 
specific sensitivity, specificity, positive predictive value 
(PPV), negative predictive value (NPV), positive (PLR) 
and negative (NLR) likelihood ratio were reported for 
PSP and further compared to those of PCT and CRP.
Approach combining biomarkers
To explore the potential added value of a model combin-
ing the biomarkers to detect infection, we fitted to the 
data three logistic regression models with biomarkers as 
continuous covariates and tested the following combina-
tions of biomarkers: PSP and CRP, PSP and PCT; PSP, 
CRP and PCT.
Statistical packages and version
All P values were two-sided, and statistical significance 
was set at a P value of less than 0.05. All analyses were 
performed using R for Windows (version 3.0.1) with the 




Among the 44 records published before March 2019 and 
identified through the literature search, 17 full-texts were 
further assessed for eligibility. Twenty-seven records were 
excluded based on review of title and abstracts. Five of 
the 17 observational studies evaluating the performance 
of PSP as a biomarker of infection in adult patients were 
finally included in the analysis (Fig. 1; Table 1). The main 
characteristics of these studies and levels of PSP, CRP and 
PCT among infected and non-infected patients are sum-
marized in Tables 1 and 2 as well as in Additional file 3: 
Figure S1. Pooled individual data from 631 patients (371 
infected and 260 non-infected) are presented in Addi-
tional file  1: Table  S10. The biomarkers were measured 
in 479 patients admitted to the intensive care unit and in 
152 admitted to the emergency room. The distributions 
of the three biomarkers significantly differed between 
infected and non-infected patients (Table  2; Additional 
file 1: Table S10, Additional file 3: Figure S3A and S3B). 
However, the overlap zone between the values of CRP 
and PCT among infected and non-infected patients was 
larger than that of PSP (Additional file 3: Figures S3A and 
S3B).
While a PSP I2 of 42% indicates only moderate hetero-
geneity in PSP ability to detect infection, the intercept I2 
of 96% indicates an important heterogeneity in baseline 
risk of infection among the studies (Additional file 3: Fig-
ure S4 and Additional file 1: Table S5). Despite the slight 
asymmetry with extreme value given by the PSP effect 
in the study of Guadiano-Romulado [6], the classical 
Egger test did not reject the null symmetry hypothesis 
corresponding to ‘no bias in publications’ (Additional 
file 3: Figure S5).
Diagnosing infection in hospitalized adult patients using 
single biomarkers and the ‘single‑fit’ fixed‑effect model
PSP performed slightly better than CRP and PCT for 
detecting infection among adult hospitalized patients 
(p = 0.044 and p = 0.010, DeLong test, Table 3). In a first 
step, using the Youden’s index [25] giving equal weight 
to both sensitivity and specificity, we identified an opti-
mal PSP cut-off value of 44.18 ng/ml that best diagnoses 
infection with an ROC AUC of 0.81 (95% CI 0.78–0.85) 
(Fig.  2A; Table  3). Using that threshold, we calculated 
the corresponding positive [0.85 (0.81–0.89)] and nega-
tive [0.63 (0.58–0.68)] predictive values for the detec-
tion of infection. The same methods were applied to CRP 
and PCT. Their respective ROC AUC values computed 
threshold values of 99.05 mg/l and 0.2 ng/ml for CRP and 
PCT, respectively, were lower: CRP 0.77 [0.73–0.80] and 
PCT 0.78 [0.74–0.82] (Fig. 2B; Table 3). Additional file 3: 
Figure S6 and Additional file 1: Table S9 display the PSP, 
CRP and PCT AUC ROC values using the defined cut-
offs presented in Table 3 and applied to each individual 
datasets of the five eligible studies.
Diagnosing infection in hospitalized adult patients using 
combinations of biomarkers
In a second step, we determined whether various com-
binations of biomarkers would improve the perfor-
mance of infection detection among adult hospitalized 
patients (Additional file 3: Figure S7 and Additional file 1: 
Table S11). The model combining PSP with CRP was bet-
ter than the one combining PSP with PCT. When com-
bining PSP to CRP, the performance increased to an ROC 
AUC of 0.90 (0.87, 0.92), with a sensitivity of 0.81 (0.77, 
0.85), specificity 0.84 (0.79, 0.90), PPV 0.91 (0.88, 0.94) 
and NPV 0.69 (0.63, 0.75). Adding PCT to the PSP + CRP 
model did not further improve performance.
Discussion
Since its first description as a potential infection bio-
marker in patients after trauma [14], pancreatic stone 
protein has repeatedly been shown to perform bet-
ter than CRP and at least as well as PCT in identifying 
patients with infection [13–15, 17, 18]. However, in con-
trast to PCT [6, 26], no cut-off threshold value has yet 
been defined for its eventual clinical use.
We were able to obtain raw data from five small obser-
vational studies and did a meta-analysis at the individual 
patient level to explore the performance of PSP in detect-
ing infection. The eligible studies were performed in dif-
ferent countries across Europe and included acutely ill 
patients from ERs or ICUs. The resulting cohort of 631 
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hospitalized adult patients encompassed an important 
proportion (42%) of patients without infection, which 
makes it the largest analysis of this nature on PSP.
Because we observed low heterogeneity of PSP effect 
despite strong heterogeneity in the baseline risk of infec-
tion among studies, we decided not to adjust for hetero-
geneity in the models presented in the main manuscript, 
because it may not be of clinical relevance (see Additional 
file 5: Supplemental section for models adjusting for het-
erogeneity). In the trade-off—adjusting for heterogene-
ity and improving performance of the biomarker versus 
addressing a clinical need and computing a unique bio-
marker threshold—we chose to omit adjustment for het-
erogeneity, especially as we wanted to determine a PSP 
cut-off value and compare it to those of PCT and CRP 
currently largely used at the bedside [6–10].
We applied a stepwise approach to evaluate the per-
formance of PSP and compared it to those of CRP 
and PCT for detecting infection in adult hospitalized 
patients presenting to the ER or the ICU. In all explored 
scenarios, PSP achieved a statistically significant bet-
ter performance compared to CRP and PCT. Using the 
Youden’s index approach, we found a PSP cut-off value 
of 44.12  ng/ml, which is approximately four-fold higher 
than the upper value previously determined in 61 healthy 
adult volunteers (min. 4.0, max 18.3, median 10.8 ng/ml) 
[27]. Using the same methodology, we found a CRP cut-
off value of 99.5 mg/l and a PCT cut-off value of 0.2 ng/
ml. Moreover, because there is much less overlap in 
PSP levels between infected and non-infected patients, 
PSP could guide decisions to start antibiotic treatment, 
as opposed to PCT that is currently rather used in ICU 
patients for antibiotic de-escalation [8, 11, 28].
The inclusion of post-trauma and post-operative pop-
ulations with a very low baseline risk of infection might 
have limited the ability of CRP and PCT to diagnose 
infection. Previous studies and meta-analysis exploring 
the diagnostic value of PCT for the detection of patients 
with infection have indeed reported that PCT accuracy 
and cut-off values are highly dependent on the clinical 
settings and the baseline risks for infection [6, 26]. On the 
other hand, this might simply have highlighted the possi-
ble advantage of PSP over PCT and CRP in particular sit-
uations characterized by severe non-infectious systemic 
inflammatory states. Two studies including patients post-
burn trauma recently confirmed this observation [29, 30]. 
Interestingly, PSP levels rose up to 72 h before the clinical 
diagnosis of infection, confirming its potential role as an 
early biomarker of infection.
We further explored the value of biomarkers combina-
tions. Combining PSP with CRP increased the accuracy 
of detecting infection from an AUC 0.81 to 0.90, a value 
that is usually considered as very good [31] and among 
the highest AUCs reported for this setting [4, 8, 9]. Inter-
estingly, adding CRP to PSP markedly increases the sen-
sitivity while not decreasing the specificity achieved by 
PSP alone (Additional file 1: Table S11).
This study has several strengths, which makes its results 
potentially generalizable. First, it was possible to include 
individual patient data of all published studies that evalu-
ated the value of PSP to detect infection in hospitalized 
patients before March 2019. Second, it encompasses 
important clinical settings—ICUs and ERs—where early 
detection of infection is of the utmost importance in 
order to guide rapid management [1]. Third, the raw data 
come from studies performed in several centres in the 
UK, Spain and Switzerland, reducing the risk of centre-
effect bias. On the other hand, the measurement of PSP 
level was consistent throughout all studies, minimizing 
the risk of methodological bias. Finally, yet importantly, 
a balanced proportion of infected and non-infected 
patients was included in this analysis.
Table 2 Characteristics of the patients’ population for each study
a Age and biomarker levels are expressed as medians [interquartile range]. # Klein et al. reported neither gender nor PCT values
Publication Agea Males (%) No infection 
 PSPa ng/ml








Infection  PCTa 
ng/ml






113 [62, 162] 0.38 [0.25, 0.54] 0.54 0.34, 1.2]
Llewelyn [15] 66 [53, 75] 108 (60%) 17.8 [11.7, 29.7] 107.75 [49.08, 
247]
10.6 [3.4, 26.5] 144.65 [104.97, 
203.05]
0.2 [0.1, 0.8] 3.1 [0.8, 8.83]
Gukasjan et al. 
[17]




51.3 [32.7, 86.4] 222.8 [144.25, 
286.55]
0.1 [0.03, 0.2] 1.07 [0.28, 6.05]














89 (59%) 22.7 [17.2, 
30.35]
73 [33.2, 203] 48 [19, 135] 130 [67, 210] 0.08 [0.06, 0.15] 0.54 [0.23, 2.45]
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The main limitation of our study is the heterogene-
ity of the included populations, mixing community- and 
healthcare-acquired infections: some populations were 
included from medical emergency admissions with 
the goal to confirm infection at admission, while other 
patients were trauma or surgical patients who were likely 
to develop infection during hospitalization. This trans-
lates into an important heterogeneity in baseline risk of 
infection among the studies. Moreover, the five studies 
included patients for whom suspected or documented 
infection was the main reason of referral, which may 
limit the generalization of the findings in other circum-
stances. In addition, because only one study considered 
patients in the ER, we could not investigate subgroup of 
patients from ERs versus ICUs.
A further important limitation of primary research in 
infection biomarker evaluation is the lack of an objective 
gold standard definition of infection. Nevertheless, each 
of the five eligible studies set out clear criteria and pro-
cedures, all consistent with one another, using a synthe-
sis of available clinical, radiological and microbiological 
evidences to assign each case as infection or not. Fur-
thermore, the fact that we find low heterogeneity of PSP 
effect across the range of studies performed is reassuring 
that our fundamental observation is not undermined by 
variability in case definition. Moreover, the ability of PSP 
to diagnose infection is confirmed across all studies.
Our study opens new possibilities for the future use of 
PSP, including being used as a tool to optimize antibiotic 
stewardship program, as a biomarker to guide the deci-
sion to start antibiotics, or as inclusion or stratification 
criteria for future studies of severe infections. PSP is now 
available at the point of care (POC) with a turnaround 
time of less than 5 min [12] making it highly suitable for 
situations where time to antibiotic is essential.
The next step would be to validate these results in inde-
pendent cohorts of patients. As baseline risk of infec-
tion impacts the performance of a diagnostic biomarker 
and its corresponding threshold, the validation process 
would require to perform independent studies in selected 
settings (primary care, ER, ICU), each including at best 
patients with a homogenous baseline risk of infection. 
Such a thorough validation process has been performed 
for PCT [6, 26] in large independent cohorts of patients, 
each with different baseline risks of infection and is still 
required before PSP to be routinely used in the clinic.
The benefit of serial measurement of PSP for the early 
detection of sepsis in intensive care unit patients has been 
evaluated in a prospective trial using the new POC tech-
nology [32]. This patient population would be the first 
ideal cohort to validate the defined threshold in a homog-
enous patient population as well as the value of combin-
ing PSP to CRP. Both biomarkers can be now measured 
using point-of-care technologies; however, correction 
factors will be required while using new measurement 
assays and technologies. Finally, our methodology can 
be used to further evaluate the value of PSP in detecting 
the severity of the infection as well as its prognosis and to 
define for thresholds for that purpose as well.
Conclusions
This study confirms that PSP is a promising biomarker 
to detect infection in hospitalized patients. Using a cut-
off value of 44.18 ng/ml, PSP performs better than CRP 
or PCT across the considered studies. The combination 
of PSP with CRP further enhance its accuracy. However, 
Fig. 2 ROC curve analysis of PSP (A) compared to the ones of CRP (red) and PCT (green) (B) for the detection of infection in adult hospitalized 
patients. The cut‑off values of the biomarkers were determined by the Youden’s index as (A) PSP 44.18 ng/ml with the corresponding ROC 
AUC = 0.81 and AUC 95% CI (0.78, 0.85); (B) CRP 99.05 mg/l with AUC 0.77 (0.73, 0.80) and PCT 0.20 ng/ml with AUC 0.78 (0.74, 0.82)
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further and especially prospective studies are needed 
to confirm its utility and safety in the daily clinical use, 
especially as a potential biomarker to guide the initiation 
of antibiotics.
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